Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.32 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.32 |
| ▸ | TBXA2R | P21731 | 2/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.32 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | CHRNA10 | Q9GZZ6 | 1/20 | 0.32 |
| ▸ | CHRNA9 | Q9UGM1 | 1/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL10633358 | 0.97 | ALDH1A1 (0.36) | TSHRACHECHRM1CHRM5CHRM3 | |
| SCHEMBL4550498 | 0.70 | ALDH1A1 (0.32) | TSHRALDH1A1 | |
| SCHEMBL29497518 | 0.67 | CA4 (0.46) | ALDH1A1 | |
| SCHEMBL30160923 | 0.67 | CA4 (0.46) | ALDH1A1 | |
| SCHEMBL8524045 | 0.67 | ALDH1A1 (0.39) | TSHRCHRM1TBXA2RALDH1A1LMNA | |
| SCHEMBL1925937 | 0.67 | ALDH1A1 (0.32) | TSHRCHRM1TBXA2RALDH1A1LMNA | |
| Hydrochloric Acid SCHEMBL31574660 | 0.66 | CA4 (0.45) | — | |
| SCHEMBL7158911 | 0.65 | — | — | |
| SCHEMBL27633145 | 0.65 | GAA (0.41) | TSHRCHRM1CHRM5CHRM3CHRM2 | |
| SCHEMBL2142716 | 0.65 | KDM4E (0.35) | ALDH1A1LMNABLM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12622913-B2 | Folate salts for medical use | APROFOL AG (CH) | 2026-05-12 | — | — | US | claimed |
| US-20230277544-A1 | FOLATE SALTS FOR MEDICAL USE | APROFOL AG (CH) | 2023-09-07 | — | — | US | claimed |
| US-20200261460-A1 | FOLATE SALTS FOR MEDICAL USE | APROFOL AG (CH) | 2020-08-20 | — | — | US | claimed |
| EP-3687995-A1 | FOLATE SALTS FOR MEDICAL USE | Aprofol AG (CH) | 2020-08-05 | — | — | EP | claimed |
| CN-111448196-A | Folates for medical use | 阿普罗福尔公司 | 2020-07-24 | — | — | CN | claimed |
| WO-2019063236-A1 | FOLATE SALTS FOR MEDICAL USE | APROFOL AG (CH) | 2019-04-04 | — | — | WO | claimed |
| EP-3461826-A1 | MULTIFUNCTIONAL FOLATE SALTS | Aprofol AG (CH) | 2019-04-03 | — | — | EP | claimed |
| US-12622913-B2 | Folate salts for medical use | APROFOL AG (CH) | 2026-05-12 | — | — | US | disclosed |
| CN-118126843-A | Monascus strain and application thereof in preparation of fermented tea | 安徽德昌药业股份有限公司 | 2024-06-04 | — | — | CN | disclosed |
| US-20230277544-A1 | FOLATE SALTS FOR MEDICAL USE | APROFOL AG (CH) | 2023-09-07 | — | — | US | disclosed |
| US-11690846-B2 | Folate salts for medical use | APROFOL AG | 2023-07-04 | — | — | US | disclosed |
| CN-107108837-B | Thermoplastic polyurethane films for delivering active agents to skin surfaces | 路博润先进材料公司 | 2021-04-13 | — | — | CN | disclosed |
| US-20200261460-A1 | FOLATE SALTS FOR MEDICAL USE | APROFOL AG (CH) | 2020-08-20 | — | — | US | disclosed |
| WO-2019063236-A1 | FOLATE SALTS FOR MEDICAL USE | APROFOL AG (CH) | 2019-04-04 | — | — | WO | disclosed |
| EP-3461826-A1 | MULTIFUNCTIONAL FOLATE SALTS | Aprofol AG (CH) | 2019-04-03 | — | — | EP | disclosed |
| WO-2008021552-A9 | BIASED LIGANDS AND METHODS OF IDENTIFYING SAME | UNIV DUKE (US) | 2008-05-29 | — | — | WO | disclosed |
| WO-2008021552-A2 | BIASED LIGANDS AND METHODS OF IDENTIFYING SAME | DUKE UNIVERSITY (US) | 2008-02-21 | — | — | WO | disclosed |
| US-6303588-B1 | APPLYING TO PORTIONS OF THE SKIN OF SUCH PATIENT WHICH HAVE ABNORMAL SKIN CELL METABOLISM BIOACTIVE AGENT COMPRISING ADENOSINE-5-TRIPHOSPHATE, QUANOSINE-5-TRIPHOSPHATE AND PHOSPHINOSITEDES AND BIOLOGICALLY ACCEPTABLE CARRIER | Danielov, Michael M. | 2001-10-16 | — | — | US | disclosed |
| US-5885974-A | DECREASES THE DOSAGE OF BIOACTIVE AGENT NECESSARY, WHEN ADMINISTERED TO A PATIENT WITH ABNORMAL CELL METABOLISM, TO CORRECT THE ABNORMAL CELL METABOLISM AND PROMOTE THE RESUMPTION OF NORMAL CELL METABOLISM | Danielov, Michael M. (US) | 1999-03-23 | — | — | US | disclosed |
| WO-1996017621-A1 | CORRECTING BIOLOGICAL INFORMATION TRANSFER USING THREE BIOLOGICAL INFORMATION BLOCKS | DNS SCIENTIFIC, INC. (US) | 1996-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200261460-A1 | FOLATE SALTS FOR MEDICAL USE | FOLR2, FOLR1, MTHFD1 | TSHR 4388/4885ACHE 1267/4885CHRM1 102/4885 |
| US-11690846-B2 | Folate salts for medical use | FOLR2, FOLR1, MTHFD1 | TSHR 4388/4885ACHE 1267/4885CHRM1 102/4885 |
| US-20230277544-A1 | FOLATE SALTS FOR MEDICAL USE | FOLR2, FOLR1, MTHFD1 | TSHR 4635/4885ACHE 1042/4885CHRM1 92/4885 |
| US-12622913-B2 | Folate salts for medical use | FOLR2, FOLR1, MTHFD1 | TSHR 4099/4885ACHE 1158/4885CHRM1 18/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.